Erythropoietin in dialysis: blood, bones, and hormones
- PMID: 34087024
- DOI: 10.1002/jbmr.4379
Erythropoietin in dialysis: blood, bones, and hormones
Comment on
-
Erythropoietin treatment and the risk of hip fractures in hemodialysis patients.J Bone Miner Res. 2021 Jul;36(7):1211-1219. doi: 10.1002/jbmr.4297. Epub 2021 May 5. J Bone Miner Res. 2021. PMID: 33949002 Free PMC article.
References
-
- United States Renal Data System. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2020. Accessed June 1, 2021. https://adr.usrds.org/2020.
-
- Wish JB. Anemia management under a bundled payment policy for dialysis: a preview for the United States from Japan. Kidney Int. 2011;79(3):265-267.
-
- Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085-2098.
-
- Pfeffer MA, Burdmann EA, Chen C-Y, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019-2032.
-
- Swaminathan S, Mor V, Mehrotra R, Trivedi AN. Effect of Medicare dialysis payment reform on use of erythropoiesis stimulating agents. Health Serv Res. 2015;50(3):790-808.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical